CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 46 enrolled
Drug / intervention
Oxymetazoline HCL 1.0% Cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03380390
NCT03380390Phase 4Completed
CompareCT.gov

Multicenter, Open-Label, Interventional Study on the Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Subjects With Rosacea

Aclaris Therapeutics, Inc.·interventional·Posted Dec 21, 2017·Updated Sep 4, 2019

In Brief

A Phase 4 clinical trial evaluating Oxymetazoline HCL 1.0% Cream and Energy-Based Therapy for Rosacea. Completed, enrolled 46 participants across 4 sites.

Detailed Summary

This study will evaluate the safety and tolerability of oxymetazoline HCl cream 1.0% when used as an adjunctive treatment to energy-based therapy for participants with moderate to severe persistent facial erythema associated with rosacea.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRosacea
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedDec 21, 2017
Enrollment StartDec 4, 2017
Primary CompletionJun 15, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.5 years ago

Interventions

Oxymetazoline HCL 1.0% Creamdrug

Oxymetazoline HCl cream 1.0% once daily application

Energy-Based Therapydevice

Energy-based therapies (Potassium Titanyl Phosphate \[KTP\], Pulsed Dye Laser \[PDL\], or Intense Pulsed Light \[IPL\])